UK markets close in 6 hours 19 minutes

Bavarian Nordic A/S (BVNRY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
7.46+0.00 (+0.03%)
At close: 12:10PM EDT

Bavarian Nordic A/S

Philip Heymans Alle 3
Hellerup 2900
Denmark
45 33 26 83 83
https://www.bavarian-nordic.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1,379

Key executives

NameTitlePayExercisedYear born
Dr. Paul John Chaplin MSc, Ph.D.CEO & President2.12MN/A1967
Mr. Henrik Juuel M.Sc.CFO & Executive VP1.18MN/A1965
Mr. Russell Thirsk M.Sc.Executive VP & COON/AN/A1968
Mr. Rolf Sass SørensenVice President of Investor Relations & CommunicationsN/AN/AN/A
Ms. Anu Helena Kerns M.Sc.Executive VP and Chief People & Sustainability OfficerN/AN/A1972
Mr. Jean-Christophe May M.B.A., Pharm.D.Executive VP & Chief Commercial OfficerN/AN/A1967
Dr. Laurence De Moerlooze Ph.D.Executive VP & Chief Medical OfficerN/AN/A1964
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Corporate governance

Bavarian Nordic A/S’s ISS governance QualityScore as of 1 March 2024 is 4. The pillar scores are Audit: 4; Board: 1; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.